$0.39
+0.01 (+2.23%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ENSC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional
Held by 3 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)NCT06500793Pharmacokinetic Tmax [Time to Maximum Plasma Concentration]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PF614 capsule, Nafamostat Mesylate | Pharmacokinetics, Healthy Volunteer | 54 | 2026-12-22 | in 125 d | 2026-05-26 |
| PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)NCT06602271Pain NRS-R area under the curve through 48 hours (AUC4-48)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: PF614 capsule, Placebo | Postoperative Pain, Acute | 320 | Aug 2026 | ≤ 12 d | 2026-01-22 |
| Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)NCT06629402Change from Baseline (pre-dose) in Time to Pain Onset (defined as time to first pain)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: PF614, Placebo | Acute Pain | 16 | 2023-11-14actual | — | 2024-10-08 |
| Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)NCT05090280Pharmacokinetic Tmax [Time to Maximum Plasma Concentration]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate | Pharmacokinetics | 111 | 2023-04-26actual | — | 2024-09-24 |
| A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)NCT05571345Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale (VAS)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PF614, Oxycodone Hydrochloride 40 mg, Placebo | Recreational Drug Use | 32 | 2022-12-23actual | — | 2024-09-24 |
| A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)NCT05567354Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale (VAS)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PF614, Oxycodone · Other: Placebo | Recreational Drug Use | 27 | 2022-08-31actual | — | 2024-09-24 |
| Evaluation of Oral PF614 Relative to OxyContin (PF614-102)NCT05043766Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PF614, Naltrexone Hydrochloride, OxyContin | Healthy Volunteers | 84 | 2022-03-21actual | — | 2024-09-24 |
| Oral Nafamostat in Healthy Volunteers (NAF-101)NCT04406415Safety and TolerabilityRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: Nafamostat Mesilate, Placebo | Pharmacokinetics | 17 | 2020-11-11actual | — | 2024-09-24 |
| Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)NCT02454712SafetyRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: PF614, Oxycodone extended-release, Naltrexone Hydrochloride | Healthy | 64 | 2018-01-18actual | — | 2024-10-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19